PBX4 and neoplasm: Furthermore, we used TIDE to find that PBX4 obtained higher predictive values (AUC > 0.5) in 13 of the 25 ICB subcohorts and had more counts of the predictive score than three existing biomarkers (tumor mutational burden (TMB), T-cell clonality (T.Clonality), and B-cell clonality (B.Clonality)) (Figure 12B).